A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer-Reference-Cited by-同舟云学术

A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

Published:2019-01-24 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Park Jieun,Cho Yong-Hee,Shin Wook-Jin,Lee Sang-Kyu,Lee JaeHeon,Kim Taehyung,Cha Pu-Hyeon,Yang Jee Sun,Cho Jaebeom,Min Do Sik,Han Gyoonhee,Lee Ho-Young,Choi Kang-Yell

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-37059-8.pdf

Reference48 articles.

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA: a cancer journal for clinicians 63, 11–30, https://doi.org/10.3322/caac.21166 (2013).

2. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. Journal international du cancer 127, 2893–2917, https://doi.org/10.1002/ijc.25516 (2010).

3. Janku, F., Stewart, D. J. & Kurzrock, R. Targeted therapy in non-small-cell lung cancer–is it becoming a reality? Nat Rev Clin Oncol 7, 401–414, https://doi.org/10.1038/nrclinonc.2010.64 (2010).

4. Ma, P. C. Personalized targeted therapy in advanced non-small cell lung cancer. Cleveland Clinic journal of medicine 79(1), eS56–60, https://doi.org/10.3949/ccjm.79.s2.12 (2012).

5. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. The lancet oncology 12, 175–180, https://doi.org/10.1016/S1470-2045 (2011).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-02-17

2. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review;Critical Reviews in Oncology/Hematology;2024-02

3. A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition;Biomedicine Hub;2023-01-19

4. Pygo1 Regulates the Behavior of Human Non-Small-Cell Lung Cancer via the Wnt/β-Catenin Pathway;Disease Markers;2022-11-08

5. Genetic alterations shaping tumor response to anti-EGFR therapies;Drug Resistance Updates;2022-09